Oric Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 11, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 11, 2024
ORIC$9.23+4.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| Years Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities: | ||
| Net loss | $(100,697) | $(89,122) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 1,032 | 966 |
| Stock-based compensation expense | 15,226 | 14,460 |
| Loss on fixed asset disposals | 22 | 40 |
| Accretion of discount on investments, net | (6,169) | (1,042) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 1,620 | 1,030 |
| Accounts payable and accrued other liabilities | 3,278 | (1,475) |
| Net cash used in operating activities | (85,688) | (75,143) |
| Cash flows from investing activities: | ||
| Acquisitions of property and equipment | (849) | (2,078) |
| Purchases of investments | (239,244) | (238,124) |
| Maturities of investments | 196,690 | 130,954 |
| Net cash used in investing activities | (43,403) | (109,248) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock and pre-funded warrants | 85,000 | 25,000 |
| Issuance costs associated with financings | (227) | (399) |
| Proceeds from issuance of common stock under ESPP | 826 | 545 |
| Proceeds from stock option exercises | 59 | 79 |
| Net cash provided by financing activities | 85,658 | 25,225 |
| Net decrease in cash, cash equivalents and restricted cash | (43,433) | (159,166) |
| Cash, cash equivalents and restricted cash at beginning of period | 67,308 | 226,474 |
| Cash, cash equivalents and restricted cash at end of period | $23,875 | $67,308 |
NOTES TO FINANCIAL STATEMENTS
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.